AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05574569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3: (Combined Interventions of both Group 1 & 2)
Description: Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
Study NCT05461625 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ACL reconstruction
Description: Anterior cruciate ligament reconstruction
Study NCT05461625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: Anterior cruciate ligament reconstruction
Study NCT05461625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL anatomic
Description: anatomic anterolateral ligament reconstruction
Study NCT05461625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL tenodesis
Description: anterolateral ligament teondesis
Study NCT04982419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: 3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
Study NCT04982419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: 3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
Study NCT04145050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate dosing
Description: The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
Study NCT05847465 — intervention group
Intervention type: OTHER
Intervention: Bike stress test
Description: This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).
Study NCT05847465 — intervention group
Intervention type: OTHER
Intervention: Heat Tolerance Test
Description: The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test.
Study NCT05847465 — intervention group
Intervention type: OTHER
Intervention: Heat nociception test
Description: This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded.
Study NCT05914155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (genetical recombination)
Description: Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
Study NCT06210035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belly-focus meditation
Description: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
Study NCT06210035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belly-focus meditation with slow breathing
Description: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
Study NCT06307132 — intervention group
Intervention type: OTHER
Intervention: Aximus capsules（test）
Description: Aximus capsules test preparation
Study NCT06307132 — intervention group
Intervention type: DRUG
Intervention: Aximus capsules（reference）
Description: Aximus capsules reference preparation
Study NCT05914155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo IV infusion every two weeks for two doses in double-blind phase.
Study NCT06576869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity orthopedic surgeries.
Description: Upper extremity orthopedic surgeries that require the use of a tourniquet.
Study NCT06576609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INJEX [ Needle less anesthesia]
Description: already described
Study NCT06576609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INJEX [ Needle less anesthesia]
Description: already described
Study NCT05760989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System
Description: Replacement of the native tricuspid valve through a transcatheter approach
Study NCT06576531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: A stepped training intervention designed ad hoc based on a combination of aerobic and strength exercises.
Study NCT06368271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipidomics
Description: Health beneficial effects of medium-chain fatty acids
Study NCT05914155 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab (genetical recombination)
Description: Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
Study NCT06029920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Walking
Description: Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
Study NCT05829629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBHPVE6E7
Description: Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
Study NCT05829629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
Study NCT05110937 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling
Study NCT05421429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 doseⅠ
Description: KN057 subcutaneous (SC) injection
Study NCT05421429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 dose Ⅱ
Description: KN057 SC injection
Study NCT05421429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 dose Ⅲ
Description: KN057 SC injection
Study NCT04756687 — intervention group
Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Administered as specified in the treatment arm.
Study NCT05659745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VM-02
Description: VM-02 is a personal care product for vaginal health.
Study NCT05452057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods.
Study NCT05659745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Commercial Oral Probiotic Competitor
Description: Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
Study NCT05659745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VM-02 Placebo
Description: VM-02 Placebo is a personal care product placebo for vaginal health.
Study NCT04618575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid combined with total glucosides of paeony
Description: Ursodeoxycholic acid combined with total glucosides of paeony
Study NCT04618575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic acid only
Description: Ursodeoxycholic acid only
Study NCT05727553 — intervention group
Intervention type: RADIATION
Intervention: Online adaptive radiotherapy
Description: Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
Study NCT05654961 — intervention group
Intervention type: OTHER
Intervention: Use of telemedicine
Description: Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
Study NCT06645808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-N-Suc-F8scFv
Description: 89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
Study NCT06645808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-N-Suc-C9scFv
Description: 89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
Study NCT06645808 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
Study NCT06670989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixation training
Description: Training (adapting) microsaccades during fixation
Study NCT06627920 — intervention group
Intervention type: DEVICE
Intervention: Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.
Description: Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
Study NCT05487664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
Study NCT05487664 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
Study NCT06700148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 1 dose of MCV4 on Day 0
Study NCT06700148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPSV4
Description: 1 dose of MPSV4 on Day0
Study NCT05499247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinQ Glow Bright Wonder Mask
Description: Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical
Study NCT06379763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing exercise
Description: 15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
Study NCT06718686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg IR tablet
Description: Drug therapy vs placebo
Study NCT06718686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT06727604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: 600 mg SC QW for 52 weeks
Study NCT06727604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: 600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
Study NCT06727604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC QW for 52 weeks
Study NCT06750692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: Mirror therapy
Description: The first group of participants will receive a total of 20 sessions of upper extremity mirror therapy program, 5 sessions per week for 4 weeks.
Study NCT06750692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Low Frequency rTMS Protocol
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) will be applied at an intensity of 100-110% of the resting motor threshold and low frequency (1 Hz) to the contralateral M1 upper extremity motor cortex region for a total of 20 sessions, 5 sessions per week for 4 weeks. rTMS application is planned to provide magnetic stimulation with the stimulator of the Magventure MagPro R30 device.
Study NCT06750692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted hand therapy
Description: In the Robot Assisted Therapy group, a total of 20 sessions will be applied 5 days a week for 4 weeks using continuous passive range of motion, active assistive exercise and play therapy programs for hemiplegic upper extremities with AMADEO (Tyromotion Austria).
Study NCT06750900 — intervention group
Intervention type: OTHER
Intervention: NORMAL CONDITION
Description: They perform 3 lumbar extensions until the onset of pain without virtual reality
Study NCT06750900 — intervention group
Intervention type: OTHER
Intervention: UNDERSTATED CONDITION
Description: They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10%less than they are really moving.
Study NCT06750900 — intervention group
Intervention type: OTHER
Intervention: OVERSTATED CONDITION
Description: They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10% more than they are really moving.
Study NCT06750861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706+AG
Study NCT06755931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quilling set
Description: After the intervention group is determined in randomization, half an hour before the cardiac catheterization and angiography procedure, without premedication treatment, the researcher will be asked to choose 2 animal and plant figures, samples of which have been previously made, through a quilling set, in cooperation with the researcher. It will be done with the child in a 15-20 minute period, accompanied by the researcher, with 2 figures chosen by the child. With the opportunity for the child to choose the color and figure he/she wants, the child will be at the center of the work. The figure will be given as a gift to the child and the survey forms will be filled out again 5 minutes after the application, before the premedication treatment. In order to prevent bias in the research, the descriptive information form and fear and anxiety scales will be taken by the evaluation of three people: the researcher, the parent and the child.
Study NCT06755931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Before the procedure, while the child is in the patient room, the details of the research will be explained, their consent will be obtained and the Introductory Information Form will be filled in by the parent, and the Fear Scale and State Anxiety Scale will be filled in by the child and the parent. After the control group is determined in randomization, the researcher will apply the posttest without premedication treatment half an hour before the cardiac catheterization and angiography procedure. No separate intervention will be applied. In accordance with ethical principles, after the procedure, 2 Quilling figures chosen by the control group and the child will be prepared with the help of the researcher, and the prepared figures will be gifted to the child.
Study NCT04079179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Study NCT06575556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT and MRI
Description: • Cardiac MRI Protocol~The cardiac MRI protocol will include cine imaging, aortic flow, and 3D navigator of the aorta. These sequences will be performed to assess aortic root dimensions, including aortic root, sinuses of Valsalva, and sinotubular junction and ascending aorta diameters.~• CT Aortography Protocol:~The CT aortography protocol will include non-contrast and contrast-enhanced CT imaging. The non-contrast images will be used for calcium scoring, while the contrast-enhanced images will be used to assess aortic root dimensions
Study NCT05835063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We Chatt communication tool
Description: This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
Study NCT05835063 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual/standard care
Description: Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
Study NCT06576713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Combiner whole genome and RNA sequencing
Description: High-throughput DNA and RNA sequencing
Study NCT06503484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Description: Patients will be instructed to perform kinesthetic motor imagery of the affected upper extremity in response to a visual cue given by the BCI system. Before the training session, 15 motor imagery tasks without neurofeedback will be recorded to calibrate the average level of individual brain activation and determine the optimal channel within the ipsilesional M1 area as the localizer. During the training session, patients will be instructed to do motor imagery. The level of HbO will be extracted from the ipsilesional M1 as the signal intensity. The signal intensity will be quantified as the percent signal change relative to the baseline. Once the signal intensity reaches the predefined individual threshold, patients will receive neurofeedback in the form of visual feedback, presented in a digital mirror therapy system (Masquer M2, SharpSight Limited, Hong Kong SAR). The visual feedback guides the patients to perform observational imitation using the affected upper limb.
Study NCT06503484 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham brain-computer interface
Description: In the sham BCI group, patients will wear identical equipment to the BCI group. However, the visual feedback presented in the digital mirror therapy system will be given based on the brain activity of another participant in the BCI group, i.e., yoked sham neurofeedback. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback. Patients will perform 15 motor imagery tasks in the calibration session, followed by 90 motor imagery tasks in the training session. The training tasks and duration will be the same as the BCI group, therefore patients will be blinded to their group allocation.
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 100 mg/mL (manufactured concentration) local TXA injection in the orbit
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
Description: 1g IV TXA
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline - injection
Description: 0.9% Normal Saline injection in the orbit
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline - injection
Description: 0.9% Normal Saline injection in the orbit
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline - intravenous
Description: 0.9% IV Normal Saline